Clinical ProgressZURA plans to initiate a Phase 2 trial of lead asset tibulizumab in hidradenitis suppurativa (HS), and they now have an active IND for this indication.
Financial StabilityZura ended 2024 with roughly $176.5M in cash and cash equivalents, which management expects to provide an operational runway through 2027.
Regulatory InteractionsThe timely launch of the Phase 2 TibuSURE trial in systemic sclerosis aligns with ZURA's stated timeline, indicating positive interactions with the FDA.